Quarterly report · Q2
3583.TEDINET S100PIIF
Period2022-04-01 → 2022-09-30
Filed2022-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥341m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥366m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥366m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥727m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥363m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥405m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥365m | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥270m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥537m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥252m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥270m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥252m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥9.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥9.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥9.2bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.8bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥4.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.1bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥190m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥649m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥44m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥189m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥114m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥266m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥21m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥97.39 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.08 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥194.04 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.19 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.71 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 59.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.2% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥12m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥344,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥12m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥4m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥696m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥693m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥44m |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥451m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥495m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥14m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥491m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥1m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | −¥14m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥697m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥695m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥2m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥77m |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥449m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥2m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥527m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥2m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥513m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 534
| Item | Context | Value | Unit |
|---|---|---|---|
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)オーベクス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都墨田区両国４－31－11 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |